MTOR and cancer: Then, through a comprehensive analysis of the Cancer Cell Line Encyclopedia (CCLE) and Genomics of Drug Sensitivity in Cancer (GDSC) databases, we identified GNE‐317, a PI3K/mTOR inhibitor that crosses the blood‐brain barrier and specifically targets Moesin.